Transplantation for Multiple Myeloma. - Wikidata - wikimedia - TriplyDB

Transplantation for Multiple Myeloma.

Transplantation for Multiple Myeloma.

http://www.wikidata.org/entity/Q38970603

about

Transplantation for Multiple Myeloma.

http://www.wikidata.org/entity/Q38970603

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Transplantation for Multiple Myeloma.

@en

type

label

Transplantation for Multiple Myeloma.

@en

prefLabel

Transplantation for Multiple Myeloma.

@en

P1433

Q38970603-EE5C3A23-3E48-4D03-8ADD-75860BDA71FC

P1476

Q38970603-16D758B7-AD5C-40E3-933A-D372AA2C2AA4

P2093

Q38970603-F1905AD3-31DD-4F8C-BAA3-4D48E3710A84

P2860

Q38970603-03265C2D-FB14-4CCB-9E57-B964AD5FE881

Q38970603-03269DBA-F5C5-4B1E-9726-41823AED559A

Q38970603-04BFB9A7-3E49-4104-9698-A2EA8F82312B

Q38970603-115B870D-11C2-48CB-8939-30B6067DB3DD

Q38970603-116AA3D5-955F-4F3E-8471-64C5D46B6D43

Q38970603-24E3663E-91EE-4AB9-98B8-2A3442BC98CF

Q38970603-2780084A-07D7-4F94-A995-C9B60E5E3BA6

Q38970603-29B8DC0C-75BD-41F5-8DF1-6340F5C87795

Q38970603-2AB42AB3-043C-49C1-8793-9650C2A59C58

Q38970603-2BE2242D-C011-4C5C-B8F0-B4E74C7DF642

P304

Q38970603-A458C965-4CCC-4082-A5A1-EA32032F529B

P31

Q38970603-9A69E475-57C0-4473-8EDB-733404201758

P356

Q38970603-511E7B89-3040-4DC7-9223-852234AE46AB

P478

Q38970603-F45D5C7B-3BC6-45B7-B27D-F0886FA2BF8E

P50

Q38970603-3F41388F-376C-4689-9AFC-5C177FC09A8F

P577

Q38970603-E7665DC7-E770-4860-B5FE-2F0B2FC0A8A7

P698

Q38970603-C59BDBAF-80C7-4B28-9CCF-F31BA43C6270

P356

978-3-319-40320-5_13

P1433

Cancer Treatment and Research

P1476

Transplantation for Multiple Myeloma.

@en

P2093

Yogesh S Jethava

http://www.w3.org/2001/XMLSchema#string

P2860

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou

Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Lenalidomide after stem-cell transplantation for multiple myeloma

A comparison of allografting with autografting for newly diagnosed myeloma.

Cryopreservation of hematopoietic stem cells.

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

P304

227-250

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/978-3-319-40320-5_13

http://www.w3.org/2001/XMLSchema#string

P478

169

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27696266

http://www.w3.org/2001/XMLSchema#string